Skip to main content
SpringerLink
Log in

Adherence to Medications in Uncontrolled Hypertension

  • Chapter
  • First Online:
Interventional Therapies for Secondary and Essential Hypertension

Part of the book series: Updates in Hypertension and Cardiovascular Protection ((UHCP))

  • 826 Accesses

Abstract

In hypertension (HTN), lowering blood pressure (BP) to the recommended targets is the most effective way to reduce both total and cardiovascular mortality in hypertensive patients and to decrease the risk of developing cardiac, renal, and neurological complications [1–3]. Today, the clinical management of essential HTN is based essentially on the recommendation of lifestyle changes such as losing weight, eating less salt or exercising more, and on the prescription of BP-lowering drugs [1]. More recently, the development of interventional treatments such as renal denervation, baroreceptor stimulation, or the creation of an iliac arteriovenous fistula has provided additional opportunities to control BP especially in patients with drug-resistant hypertension (dRHTN) [4–6].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

BP:

Blood pressure

dRHTN:

Drug-resistant hypertension

HTN:

Hypertension

References

  1. ESH/ESC Task Force for the Management of Arterial Hypertension (2013) 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 31(10):1925–1938

    Article  Google Scholar 

  2. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311(5):507–520

    Article  CAS  PubMed  Google Scholar 

  3. National Clinical Guideline C (2011) National Institute for Health and Clinical Excellence: Guidance. Hypertension: the clinical management of primary hypertension in adults: update of clinical guidelines 18 and 34. Royal College of Physicians (UK) National Clinical Guideline Centre, London

    Google Scholar 

  4. Vongpatanasin W (2014) Resistant hypertension: a review of diagnosis and management. JAMA 311(21):2216–2224

    Article  PubMed  Google Scholar 

  5. Victor RG (2015) Carotid baroreflex activation therapy for resistant hypertension. Nat Rev Cardiol 12(8):451–463

    Article  PubMed  Google Scholar 

  6. Lobo MD, Sobotka PA, Stanton A, Cockcroft JR, Sulke N, Dolan E et al (2015) Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet 385(9978):1634–1641

    Article  PubMed  Google Scholar 

  7. Mancia G, Messerli F, Bakris G, Zhou Q, Champion A, Pepine CJ (2007) Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 50(2):299–305

    Article  CAS  PubMed  Google Scholar 

  8. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G et al (2011) Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 29(3):610–618

    Article  CAS  PubMed  Google Scholar 

  9. Naderi SH, Bestwick JP, Wald DS (2012) Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 125(9):882–887 e1

    Article  PubMed  Google Scholar 

  10. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T et al (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73(5):691–705

    Article  PubMed  PubMed Central  Google Scholar 

  11. Blaschke TF, Osterberg L, Vrijens B, Urquhart J (2012) Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol 52:275–301

    Article  CAS  PubMed  Google Scholar 

  12. Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J (2013) Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension 62(2):218–225

    Article  CAS  PubMed  Google Scholar 

  13. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M (2008) Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 336(7653):1114–1117

    Article  PubMed  PubMed Central  Google Scholar 

  14. Qvarnstrom M, Kahan T, Kieler H, Brandt L, Hasselstrom J, Bengtsson Bostrom K et al (2013) Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J Clin Pharmacol 69(11):1955–1964

    Article  PubMed  Google Scholar 

  15. Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifiro G, Cricelli C et al (2005) Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 23(11):2093–2100

    Article  CAS  PubMed  Google Scholar 

  16. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD (1999) Persistence with treatment for hypertension in actual practice. CMAJ 160(1):31–37

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Mancia G, Parodi A, Merlino L, Corrao G (2011) Heterogeneity in antihypertensive treatment discontinuation between drugs belonging to the same class. J Hypertens 29(5):1012–1018

    Article  CAS  PubMed  Google Scholar 

  18. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD (1999) Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 160(1):41–46

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Burnier M, Brede Y, Lowy A (2011) Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril. Int J Clin Pract 65(2):127–133

    Article  CAS  PubMed  Google Scholar 

  20. Morisky DE, Ang A, Krousel-Wood M, Ward HJ (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 10(5):348–354

    Article  Google Scholar 

  21. Shi L, Liu J, Koleva Y, Fonseca V, Kalsekar A, Pawaskar M (2010) Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics 28(12):1097–1107

    Article  PubMed  Google Scholar 

  22. Pandey A, Raza F, Velasco A, Brinker S, Ayers C, Das SR et al (2015) Comparison of Morisky Medication Adherence Scale with therapeutic drug monitoring in apparent treatment-resistant hypertension. J Am Soc Hypertens 9(6):420–426 e2

    Article  PubMed  Google Scholar 

  23. Lee JY, Kusek JW, Greene PG, Bernhard S, Norris K, Smith D et al (1996) Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am J Hypertens 9(8):719–725

    Article  CAS  PubMed  Google Scholar 

  24. Halpern MT, Khan ZM, Schmier JK, Burnier M, Caro JJ, Cramer J et al (2006) Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 47(6):1039–1048

    Article  CAS  PubMed  Google Scholar 

  25. Burnier M, Schneider MP, Chiolero A, Stubi CL, Brunner HR (2001) Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 19(2):335–341

    Article  CAS  PubMed  Google Scholar 

  26. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H et al (2013) Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 31(4):766–774

    Article  CAS  PubMed  Google Scholar 

  27. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J et al (2014) High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart (British Cardiac Society) 100(11):855–861

    CAS  Google Scholar 

  28. Brinker S, Pandey A, Ayers C, Price A, Raheja P, Arbique D et al (2014) Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol 63(8):834–835

    Article  PubMed  Google Scholar 

  29. Cramer JA, Scheyer RD, Mattson RH (1990) Compliance declines between clinic visits. Arch Intern Med 150(7):1509–1510

    Article  CAS  PubMed  Google Scholar 

  30. Chung O, Vongpatanasin W, Bonaventura K, Lotan Y, Sohns C, Haverkamp W et al (2014) Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. J Hypertens 32(12):2411–2421

    Google Scholar 

  31. Demonceau J, Ruppar T, Kristanto P, Hughes DA, Fargher E, Kardas P et al (2013) Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. Drugs 73(6):545–562

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Beaussier H, Boutouyrie P, Bobrie G, Frank M, Laurent S, Coudore F et al (2015) True antihypertensive efficacy of sequential nephron blockade in patients with resistant hypertension and confirmed medication adherence. J Hypertens 33(12):2526–2533

    Article  CAS  PubMed  Google Scholar 

  33. Burnier M, Wuerzner G (2015) Drug adherence monitoring in clinical trials: a necessity for a correct assessment of the efficacy and safety of antihypertensive therapies. J Hypertens 33(12):2395–2398

    Article  CAS  PubMed  Google Scholar 

  34. Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE et al (2014) Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 63(5):991–999

    Article  CAS  PubMed  Google Scholar 

  35. Wetzels GE, Nelemans PJ, Schouten JS, Dirksen CD, van der Weijden T, Stoffers HE et al (2007) Electronic monitoring of adherence as a tool to improve blood pressure control. A randomized controlled trial. Am J Hypertens 20(2):119–125

    Article  PubMed  Google Scholar 

  36. Christensen A, Osterberg LG, Hansen EH (2009) Electronic monitoring of patient adherence to oral antihypertensive medical treatment: a systematic review. J Hypertens 27(8):1540–1551

    Article  CAS  PubMed  Google Scholar 

  37. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F (2006) Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 12(3):239–245

    PubMed  Google Scholar 

  38. Mallion JM, Baguet JP, Siche JP, Tremel F, de Gaudemaris R (1998) Compliance, electronic monitoring and antihypertensive drugs. J Hypertens Suppl 16(1):S75–S79

    CAS  PubMed  Google Scholar 

  39. Perreault S, Dragomir A, Roy L, White M, Blais L, Lalonde L et al (2010) Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol 69(1):74–84

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Perreault S, Dragomir A, White M, Lalonde L, Blais L, Berard A (2009) Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med 266(2):207–218

    Article  CAS  PubMed  Google Scholar 

  41. Kettani FZ, Dragomir A, Cote R, Roy L, Berard A, Blais L et al (2009) Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 40(1):213–220

    Article  PubMed  Google Scholar 

  42. Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A, Mittmann N et al (2002) Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 24(2):302–316

    Article  PubMed  Google Scholar 

  43. Morris AB, Li J, Kroenke K, Bruner-England TE, Young JM, Murray MD (2006) Factors associated with drug adherence and blood pressure control in patients with hypertension. Pharmacotherapy 26(4):483–492

    Article  PubMed  Google Scholar 

  44. Turner BJ, Hollenbeak C, Weiner MG, Ten Have T, Roberts C (2009) Barriers to adherence and hypertension control in a racially diverse representative sample of elderly primary care patients. Pharmacoepidemiol Drug Saf 18(8):672–681

    Article  PubMed  Google Scholar 

  45. Neri L, Martini A, Andreucci VE, Gallieni M, Rey LA, Brancaccio D et al (2011) Regimen complexity and prescription adherence in dialysis patients. Am J Nephrol 34(1):71–76

    Article  PubMed  Google Scholar 

  46. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A (2006) Initial non-compliance with antihypertensive monotherapy is followed by complete discontinuation of antihypertensive therapy. Pharmacoepidemiol Drug Saf 15(8):587–593

    Article  PubMed  Google Scholar 

  47. Smith SM, Gong Y, Handberg E, Messerli FH, Bakris GL, Ahmed A et al (2014) Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens 32(3):635–643

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Thomas G, Xie D, Chen HY, Anderson AH, Appel LJ, Bodana S et al (2016) Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the chronic renal insufficiency cohort study. Hypertension 67(2):387–396

    CAS  PubMed  Google Scholar 

  49. Howard VJ, Tanner RM, Anderson A, Irvin MR, Calhoun DA, Lackland DT et al (2015) Apparent treatment-resistant hypertension among individuals with history of stroke or transient ischemic attack. Am J Med 128(7):707–714, e2

    Article  PubMed  PubMed Central  Google Scholar 

  50. Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL et al (2014) Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 64(5):1012–1021

    Article  CAS  PubMed  Google Scholar 

  51. Persu A, Jin Y, Baelen M, Vink E, Verloop WL, Schmidt B et al (2014) Eligibility for renal denervation: experience at 11 European expert centers. Hypertension 63(6):1319–1325

    Article  CAS  PubMed  Google Scholar 

  52. Burnier M, Wuerzner G (2014) Ambulatory blood pressure and adherence monitoring: diagnosing pseudoresistant hypertension. Semin Nephrol 34(5):498–505

    Article  PubMed  Google Scholar 

  53. Bertholet N, Favrat B, Fallab-Stubi CL, Brunner HR, Burnier M (2000) Why objective monitoring of compliance is important in the management of hypertension. J Clin Hypertens (Greenwich) 2(4):258–262

    Google Scholar 

  54. Strauch B, Petrak O, Zelinka T, Rosa J, Somloova Z, Indra T et al (2013) Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 31(12):2455–2461

    Article  CAS  PubMed  Google Scholar 

  55. Glynn LG, Murphy AW, Smith SM, Schroeder K, Fahey T (2010) Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev (3):Cd005182

    Google Scholar 

  56. Gwadry-Sridhar FH, Manias E, Lal L, Salas M, Hughes DA, Ratzki-Leewing A et al (2013) Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR medication adherence and persistence special interest group. Value Health 16(5):863–871

    Article  PubMed  Google Scholar 

  57. Ogedegbe G, Schoenthaler A (2006) A systematic review of the effects of home blood pressure monitoring on medication adherence. J Clin Hypertens (Greenwich) 8(3):174–180

    Article  Google Scholar 

  58. McManus RJ, Mant J, Haque MS, Bray EP, Bryan S, Greenfield SM et al (2014) Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. JAMA 312(8):799–808

    Article  CAS  PubMed  Google Scholar 

  59. Burnier M, Brown RE, Ong SH, Keskinaslan A, Khan ZM (2009) Issues in blood pressure control and the potential role of single-pill combination therapies. Int J Clin Pract 63(5):790–798

    Article  CAS  PubMed  Google Scholar 

  60. Castellano JM, Sanz G, Penalvo JL, Bansilal S, Fernandez-Ortiz A, Alvarez L et al (2014) A polypill strategy to improve adherence: results from the FOCUS (Fixed-dose Combination Drug for Secondary Cardiovascular Prevention) Project. J Am Coll Cardiol 64:2071–2082

    Article  PubMed  Google Scholar 

  61. McAlister FA, Feldman RD, Wyard K, Brant R, Campbell NR, Force CORT (2009) The impact of the Canadian Hypertension Education Programme in its first decade. Eur Heart J 30(12):1434–1439

    Article  PubMed  Google Scholar 

  62. Van Zuilen AD, Wetzels JF, Bots ML, Van Blankestijn PJ (2008) MASTERPLAN: study of the role of nurse practitioners in a multifactorial intervention to reduce cardiovascular risk in chronic kidney disease patients. J Nephrol 21(3):261–267

    PubMed  Google Scholar 

  63. Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G (2011) Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med 171(16):1441–1453

    Article  CAS  PubMed  Google Scholar 

  64. Santschi V, Chiolero A, Colosimo AL, Platt RW, Taffe P, Burnier M et al (2014) Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc 3(2):e000718

    Article  PubMed  PubMed Central  Google Scholar 

  65. Chapman RH, Ferrufino CP, Kowal SL, Classi P, Roberts CS (2010) The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs*. Int J Clin Pract 64(2):169–181

    Article  CAS  PubMed  Google Scholar 

  66. Redon J, Coca A, Lazaro P, Aguilar MD, Cabanas M, Gil N et al (2010) Factors associated with therapeutic inertia in hypertension: validation of a predictive model. J Hypertens 28(8):1770–1777

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service of Nephrology and Hypertension, Department of Medicine, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 17, Lausanne, 1011, Switzerland

    Michel Burnier & Gregoire Wuerzner

Authors
  1. Michel Burnier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregoire Wuerzner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michel Burnier .

Editor information

Editors and Affiliations

  1. First Cardiology Clinic, National and Kapodistrian University of Athens, Athens, Greece

    Costas Tsioufis

  2. Department of Nephrology and Hypertension, University Hospital Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany

    Roland E. Schmieder

  3. IRCCS Istituto Auxologico Italiano, University Milano-Bicocca, Milano Monza, Italy

    Giuseppe Mancia

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Burnier, M., Wuerzner, G. (2016). Adherence to Medications in Uncontrolled Hypertension. In: Tsioufis, C., Schmieder, R., Mancia, G. (eds) Interventional Therapies for Secondary and Essential Hypertension. Updates in Hypertension and Cardiovascular Protection. Springer, Cham. https://doi.org/10.1007/978-3-319-34141-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-34141-5_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-34140-8

  • Online ISBN: 978-3-319-34141-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation